Michaela Strobelberger

TL;DR: Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.

TL;DR: In this paper, the benefits and harms of bupropion, citalopram, desvenlafaxine, duloxetine, escitaloprams, fluoxetines, fluvoxamine, mirtazapine, nefazodone, paroxetinedine, sertraline, trazodone and venlaxine were compared for the treatment of depressive disorders.

TL;DR: The available evidence indicates that for some women with early invasive breast cancer SLND appears to be a justifiable alternative to ALND, although prognostic tumour characteristics varied among the 3 study-populations.

TL;DR: In this article, the benefits and harms of second-generation antidepressants for treating major depressive disorder in adults were compared on the basis of 234 studies, and no clinically relevant differences in the two groups were found.

TL;DR: No substantial differences in efficacy and frequent adverse events among ER opioids for cancer pain are indicated in randomized controlled trials and observational studies compared.